This study focuses on older adults with a newly diagnosed type of cancer called B-cell precursor Acute Lymphoblastic Leukemia. Specifically, the study looks at patients who are Philadelphia-negative, which means their cancer cells do not have a specific genetic marker. The purpose of the study is to compare a new treatment approach to the current standard of care to see how well it works and how safe it is.
Participants may receive different combinations of medications. One group will receive blinatumomab alternating with low-intensity chemotherapy, which is a type of treatment that uses drugs to kill cancer cells. The other group will receive the standard of care, which includes medications such as rituximab, cytarabine, dexamethasone, vincristine sulfate, cyclophosphamide, methotrexate sodium, mercaptopurine, prednisone, idarubicin, asparaginase, and doxorubicin. Other substances mentioned in the study include pegaspargase, crisantaspase, and prednisolone.
The study will monitor how long patients live and how long they stay without the cancer returning. Researchers will also look at the minimal residual disease, which refers to the small number of cancer cells that remain in the body after treatment. Additionally, the study will track how the treatments affect the patients’ quality of life, including levels of pain, tiredness, and physical function.
Who Can Join the Study?
You must give informed consent, which means you or your legal representative agrees to take part in the study after understanding all the details, before any study steps begin.
You must be 55 years of age or older.
You may be between 40 and 54 years of age if you have certain comorbidities, which are other medical conditions present at the same time as your leukemia, such as:
A history of severe pancreatitis (inflammation of the pancreas).
Diabetes mellitus that has caused damage to organs like the eyes, kidneys, or nerves.
Severe liver disease, such as cirrhosis (permanent scarring of the liver) with high pressure in the veins or a history of bleeding in the food pipe, accompanied by very high liver enzyme levels.
A body mass index (BMI) of 40 or higher combined with metabolic issues.
Other serious health conditions that make standard intensive chemotherapy too difficult to handle.
You must have a new diagnosis of Philadelphia-negative B-cell precursor acute lymphoblastic leukemia (ALL), which is a specific type of cancer found in the white blood cells.
Your ECOG performance status must be 2 or lower, which is a scale used to measure how well you can perform daily activities; a higher score may be allowed if it is caused by your leukemia.
Your kidney function must be adequate, measured by how well your kidneys filter waste from your blood.
Your liver function must be adequate, specifically looking at your total bilirubin levels, unless you have a specific harmless condition called Gilbert’s Disease or the cancer has spread to the liver.
Your heart function must be adequate, meaning your heart must pump blood effectively (measured by left ventricular ejection fraction) and you must not have uncontrolled or recent heart disease, such as a myocardial infarction (heart attack) or stroke within the last 3 months.
Who Cannot Join the Study?
You cannot participate if you have active CNS leukemia, which means cancer cells are currently present in your central nervous system (the brain and spinal cord), as confirmed by a lumbar puncture (a procedure where a needle is used to collect fluid from the spinal canal).
You cannot participate if you have had another type of malignancy (cancer) within the last 3 years, unless it was a specific type of skin, cervical, breast, or prostate cancer that was fully treated and is no longer active.
You cannot participate if you have CNS pathology, which refers to any medical conditions or damage affecting the brain or spinal cord, such as epilepsy (seizures), paresis (muscle weakness), aphasia (difficulty speaking or understanding language), stroke, dementia (memory loss and mental decline), or Parkinson’s disease.
You cannot participate if you have a psychiatric condition (mental health disorder) that would prevent you from taking high doses of corticosteroids (strong anti-inflammatory medicines).
You cannot participate if you currently have or have a history of autoimmune disease (a condition where the immune system mistakenly attacks the body) that could affect the brain or spinal cord.
You cannot participate if you have a known infection with HIV (the virus that causes AIDS).
You cannot participate if you have an active or chronic infection of Hepatitis B or Hepatitis C (viruses that cause liver inflammation).
You cannot participate if you show any signs or symptoms of an acute infection (a sudden, severe infection) or an uncontrolled chronic infection (a long-term infection that is not being managed).
You cannot participate if you have already received cancer chemotherapy (drugs used to kill cancer cells) for this specific leukemia, unless it was IT chemotherapy (medicine injected directly into the spinal fluid) or specific preparation medicine.
You cannot participate if you are currently taking part in another study testing a new drug or medical device, or if you finished a different study less than 30 days ago.
B-cell precursor Acute Lymphoblastic Leukemia – This is a type of cancer that affects the white blood cells, specifically the immature cells known as precursors. These abnormal cells accumulate in the bone marrow and blood, interfering with the production of normal blood cells. The disease can progress by spreading from the bone marrow to other parts of the body, such as the lymph nodes, spleen, or liver. It is characterized by the rapid multiplication of these cancerous cells.
The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Austria 
Belgium 
Bulgaria 
Czechia 
Denmark 
Estonia 
Finland 
France 
Greece 
Hungary 
Italy 
Portugal 
Romania 
Slovakia 
Spain 
Sweden 
The Netherlands 